(Q44712175)

5 December 2017

Humanized anti-CD20 monoclonal antibody (Rituximab) treatment for post-transplant lymphoproliferative disorder (English)

1 reference

post-transplant lymphoproliferative disorder

5 December 2017

0 references

1 reference

1 reference

1 reference

Vasundhara Ganne

1

1 reference

5 December 2017

Nauman Siddiqi

2

1 reference

5 December 2017

Bal Kamaplath

3

1 reference

5 December 2017

Chung-Che Chang

4

1 reference

5 December 2017

Eric P Cohen

5

1 reference

5 December 2017

Barbara A Bresnahan

6

1 reference

5 December 2017

Sundaram Hariharan

7

1 reference

5 December 2017

1 October 2003

1 reference

5 December 2017

Clinical Transplantation

1 reference

5 December 2017

17

1 reference

5 December 2017

5

1 reference

5 December 2017

417-422

1 reference

Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy

5 December 2017

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-0012.2003.00054.X

Posttransplant lymphoproliferative disorders in adult and pediatric renal transplant patients receiving tacrolimus-based immunosuppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-0012.2003.00054.X

Radioimmunotherapy of B-cell lymphoma with [131I]anti-B1 (anti-CD20) antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-0012.2003.00054.X

Humanized anti-CD20 monoclonal antibody (Rituximab) in post transplant B-lymphoproliferative disorder: a retrospective analysis on 32 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-0012.2003.00054.X

Epstein-Barr virus, immunodeficiency, and B cell lymphoproliferation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-0012.2003.00054.X

7 January 2021

Cancers complicating organ transplantation

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-0012.2003.00054.X

7 January 2021

Treatment of severe Epstein-Barr virus-induced lymphoproliferative syndrome with ganciclovir: two cases after solid organ transplantation

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-0012.2003.00054.X

7 January 2021

Anti-B-cell monoclonal antibodies in the treatment of severe B-cell lymphoproliferative syndrome following bone marrow and organ transplantation.

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-0012.2003.00054.X

7 January 2021

Increased incidence of lymphoproliferative disorder after immunosuppression with the monoclonal antibody OKT3 in cardiac-transplant recipients

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-0012.2003.00054.X

7 January 2021

Are post-transplant lymphomas inevitable?

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-0012.2003.00054.X

7 January 2021

Pretransplantation assessment of the risk of lymphoproliferative disorder

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-0012.2003.00054.X

7 January 2021

Posttransplant lymphoproliferative disease in primary Epstein-Barr virus infection after liver transplantation: the role of cytomegalovirus disease

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-0012.2003.00054.X

7 January 2021

Treatment of posttransplant lymphoproliferative disorder with the anti-CD20 monoclonal antibody rituximab alone in an adult after liver transplantation: a new drug in therapy of patients with posttransplant lymphoproliferative disorder after solid o

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-0012.2003.00054.X

7 January 2021

10.1034/J.1399-0012.2003.00054.X

Identifiers

DOI

1 reference

5 December 2017

1 reference